Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 68

1.

Prognostic significance of molecular subgroups of medulloblastoma in young children receiving irradiation-sparing regimens.

Yeo KK, Margol AS, Kennedy RJ, Hung L, Robison NJ, Dhall G, Asgharzadeh S.

J Neurooncol. 2019 Oct 16. doi: 10.1007/s11060-019-03307-8. [Epub ahead of print]

PMID:
31621042
2.

Noncovalent interactions of bovine trypsin with curcumin and effect on stability, structure, and function.

Rajabi M, Farhadian S, Shareghi B, Asgharzadeh S, Momeni L.

Colloids Surf B Biointerfaces. 2019 Aug 10;183:110287. doi: 10.1016/j.colsurfb.2019.06.017. [Epub ahead of print]

PMID:
31476687
3.

Improvements to the Escalation with Overdose Control design and a comparison with the restricted Continual Reassessment Method.

Ji L, Lewinger JP, Krailo M, Groshen S, Conti DV, Asgharzadeh S, Sposto R.

Pharm Stat. 2019 Jun 25. doi: 10.1002/pst.1955. [Epub ahead of print]

PMID:
31237419
4.

Enhancing Natural Killer and CD8+ T Cell-Mediated Anticancer Cytotoxicity and Proliferation of CD8+ T Cells with HLA-E Monospecific Monoclonal Antibodies.

Ravindranath MH, Filippone EJ, Devarajan A, Asgharzadeh S.

Monoclon Antib Immunodiagn Immunother. 2019 Apr;38(2):38-59. doi: 10.1089/mab.2018.0043. Review.

5.

Myc and Loss of p53 Cooperate to Drive Formation of Choroid Plexus Carcinoma.

Wang J, Merino DM, Light N, Murphy BL, Wang YD, Guo X, Hodges AP, Chau LQ, Liu KW, Dhall G, Asgharzadeh S, Kiehna EN, Shirey RJ, Janda KD, Taylor MD, Malkin D, Ellison DW, VandenBerg SR, Eberhart CG, Sears RC, Roussel MF, Gilbertson RJ, Wechsler-Reya RJ.

Cancer Res. 2019 May 1;79(9):2208-2219. doi: 10.1158/0008-5472.CAN-18-2565. Epub 2019 Mar 18.

PMID:
30885981
6.

Experimental and theoretical investigations on the interaction of l-methionine molecules with α-chymotrypsin in the aqueous solution using various methods.

Asgharzadeh S, Shareghi B, Farhadian S.

Int J Biol Macromol. 2019 Jun 15;131:548-556. doi: 10.1016/j.ijbiomac.2019.03.080. Epub 2019 Mar 13.

PMID:
30876904
7.

Applying Two Different Bioinformatic Approaches to Discover Novel Genes Associated with Hereditary Hearing Loss via Whole-Exome Sequencing: ENDEAVOUR and HomozygosityMapper.

Pourreza MR, Mohammadi H, Sadeghian L, Asgharzadeh S, Sehhati M, Tabatabaiefar MA.

Adv Biomed Res. 2018 Oct 31;7:141. doi: 10.4103/abr.abr_80_18. eCollection 2018.

8.

Challenges and perspectives of child labor.

Radfar A, Asgharzadeh SAA, Quesada F, Filip I.

Ind Psychiatry J. 2018 Jan-Jun;27(1):17-20. doi: 10.4103/ipj.ipj_105_14. Review.

9.

Clinically Relevant Cytotoxic Immune Cell Signatures and Clonal Expansion of T-Cell Receptors in High-Risk MYCN-Not-Amplified Human Neuroblastoma.

Wei JS, Kuznetsov IB, Zhang S, Song YK, Asgharzadeh S, Sindiri S, Wen X, Patidar R, Najaraj S, Walton A, Auvil JMG, Gerhard DS, Yuksel A, Catchpoole D, Hewitt SM, Sondel PM, Seeger R, Maris JM, Khan J.

Clin Cancer Res. 2018 Nov 15;24(22):5673-5684. doi: 10.1158/1078-0432.CCR-18-0599. Epub 2018 May 21.

10.

Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients.

Depuydt P, Boeva V, Hocking TD, Cannoodt R, Ambros IM, Ambros PF, Asgharzadeh S, Attiyeh EF, Combaret V, Defferrari R, Fischer M, Hero B, Hogarty MD, Irwin MS, Koster J, Kreissman S, Ladenstein R, Lapouble E, Laureys G, London WB, Mazzocco K, Nakagawara A, Noguera R, Ohira M, Park JR, Pötschger U, Theissen J, Tonini GP, Valteau-Couanet D, Varesio L, Versteeg R, Speleman F, Maris JM, Schleiermacher G, De Preter K.

J Natl Cancer Inst. 2018 Oct 1;110(10):1084-1093. doi: 10.1093/jnci/djy022.

11.

Cross-Cohort Analysis Identifies a TEAD4-MYCN Positive Feedback Loop as the Core Regulatory Element of High-Risk Neuroblastoma.

Rajbhandari P, Lopez G, Capdevila C, Salvatori B, Yu J, Rodriguez-Barrueco R, Martinez D, Yarmarkovich M, Weichert-Leahey N, Abraham BJ, Alvarez MJ, Iyer A, Harenza JL, Oldridge D, De Preter K, Koster J, Asgharzadeh S, Seeger RC, Wei JS, Khan J, Vandesompele J, Mestdagh P, Versteeg R, Look AT, Young RA, Iavarone A, Lasorella A, Silva JM, Maris JM, Califano A.

Cancer Discov. 2018 May;8(5):582-599. doi: 10.1158/2159-8290.CD-16-0861. Epub 2018 Mar 6.

12.

MYC-family protein overexpression and prominent nucleolar formation represent prognostic indicators and potential therapeutic targets for aggressive high-MKI neuroblastomas: a report from the children's oncology group.

Niemas-Teshiba R, Matsuno R, Wang LL, Tang XX, Chiu B, Zeki J, Coburn J, Ornell K, Naranjo A, Van Ryn C, London WB, Hogarty MD, Gastier-Foster JM, Look AT, Park JR, Maris JM, Cohn SL, Seeger RC, Asgharzadeh S, Ikegaki N, Shimada H.

Oncotarget. 2017 Dec 15;9(5):6416-6432. doi: 10.18632/oncotarget.23740. eCollection 2018 Jan 19.

13.

Rare MYC-amplified Neuroblastoma With Large Cell Histology.

Matsuno R, Gifford AJ, Fang J, Warren M, Lukeis RE, Trahair T, Sugimoto T, Marachelian A, Asgharzadeh S, Maris JM, Ikegaki N, Shimada H.

Pediatr Dev Pathol. 2018 Sep-Oct;21(5):461-466. doi: 10.1177/1093526617749670. Epub 2018 Feb 9.

PMID:
29426276
14.

Tumor-associated macrophages promote neuroblastoma via STAT3 phosphorylation and up-regulation of c-MYC.

Hadjidaniel MD, Muthugounder S, Hung LT, Sheard MA, Shirinbak S, Chan RY, Nakata R, Borriello L, Malvar J, Kennedy RJ, Iwakura H, Akamizu T, Sposto R, Shimada H, DeClerck YA, Asgharzadeh S.

Oncotarget. 2017 Sep 16;8(53):91516-91529. doi: 10.18632/oncotarget.21066. eCollection 2017 Oct 31.

15.

Cancer-Associated Fibroblasts Share Characteristics and Protumorigenic Activity with Mesenchymal Stromal Cells.

Borriello L, Nakata R, Sheard MA, Fernandez GE, Sposto R, Malvar J, Blavier L, Shimada H, Asgharzadeh S, Seeger RC, DeClerck YA.

Cancer Res. 2017 Sep 15;77(18):5142-5157. doi: 10.1158/0008-5472.CAN-16-2586. Epub 2017 Jul 7.

16.

NK Cell-derived Exosomes From NK Cells Previously Exposed to Neuroblastoma Cells Augment the Antitumor Activity of Cytokine-activated NK Cells.

Shoae-Hassani A, Hamidieh AA, Behfar M, Mohseni R, Mortazavi-Tabatabaei SA, Asgharzadeh S.

J Immunother. 2017 Sep;40(7):265-276. doi: 10.1097/CJI.0000000000000179.

PMID:
28622272
17.

Expression of Five Neuroblastoma Genes in Bone Marrow or Blood of Patients with Relapsed/Refractory Neuroblastoma Provides a New Biomarker for Disease and Prognosis.

Marachelian A, Villablanca JG, Liu CW, Liu B, Goodarzian F, Lai HA, Shimada H, Tran HC, Parra JA, Gallego R, Bedrossian N, Young S, Czarnecki S, Kennedy R, Weiss BD, Goldsmith K, Granger M, Matthay KK, Groshen S, Asgharzadeh S, Sposto R, Seeger RC.

Clin Cancer Res. 2017 Sep 15;23(18):5374-5383. doi: 10.1158/1078-0432.CCR-16-2647. Epub 2017 May 30.

18.

TGFβR1 Blockade with Galunisertib (LY2157299) Enhances Anti-Neuroblastoma Activity of the Anti-GD2 Antibody Dinutuximab (ch14.18) with Natural Killer Cells.

Tran HC, Wan Z, Sheard MA, Sun J, Jackson JR, Malvar J, Xu Y, Wang L, Sposto R, Kim ES, Asgharzadeh S, Seeger RC.

Clin Cancer Res. 2017 Feb 1;23(3):804-813. doi: 10.1158/1078-0432.CCR-16-1743. Epub 2016 Oct 10.

19.

BarTeL, a Genetically Versatile, Bioluminescent and Granule Neuron Precursor-Targeted Mouse Model for Medulloblastoma.

Shackleford GM, Shi XH, Swanson KS, Mahdi MY, Gonzalez-Gomez I, Asgharzadeh S, D'Apuzzo M, Erdreich-Epstein A, Moats RA.

PLoS One. 2016 Jun 16;11(6):e0156907. doi: 10.1371/journal.pone.0156907. eCollection 2016.

20.

MYCN controls an alternative RNA splicing program in high-risk metastatic neuroblastoma.

Zhang S, Wei JS, Li SQ, Badgett TC, Song YK, Agarwal S, Coarfa C, Tolman C, Hurd L, Liao H, He J, Wen X, Liu Z, Thiele CJ, Westermann F, Asgharzadeh S, Seeger RC, Maris JM, Guidry Auvil JM, Smith MA, Kolaczyk ED, Shohet J, Khan J.

Cancer Lett. 2016 Feb 28;371(2):214-24. doi: 10.1016/j.canlet.2015.11.045. Epub 2015 Dec 10.

21.

More than the genes, the tumor microenvironment in neuroblastoma.

Borriello L, Seeger RC, Asgharzadeh S, DeClerck YA.

Cancer Lett. 2016 Sep 28;380(1):304-14. doi: 10.1016/j.canlet.2015.11.017. Epub 2015 Nov 17. Review.

22.

A LIN28B-RAN-AURKA Signaling Network Promotes Neuroblastoma Tumorigenesis.

Schnepp RW, Khurana P, Attiyeh EF, Raman P, Chodosh SE, Oldridge DA, Gagliardi ME, Conkrite KL, Asgharzadeh S, Seeger RC, Madison BB, Rustgi AK, Maris JM, Diskin SJ.

Cancer Cell. 2015 Nov 9;28(5):599-609. doi: 10.1016/j.ccell.2015.09.012. Epub 2015 Oct 17.

23.

Disseminated Medulloblastoma in a Child with Germline BRCA2 6174delT Mutation and without Fanconi Anemia.

Xu J, Margol AS, Shukla A, Ren X, Finlay JL, Krieger MD, Gilles FH, Couch FJ, Aziz M, Fung ET, Asgharzadeh S, Barrett MT, Erdreich-Epstein A.

Front Oncol. 2015 Aug 27;5:191. doi: 10.3389/fonc.2015.00191. eCollection 2015.

24.

Molecular subgroups of medulloblastoma identification using noninvasive magnetic resonance spectroscopy.

Blüml S, Margol AS, Sposto R, Kennedy RJ, Robison NJ, Vali M, Hung LT, Muthugounder S, Finlay JL, Erdreich-Epstein A, Gilles FH, Judkins AR, Krieger MD, Dhall G, Nelson MD, Asgharzadeh S.

Neuro Oncol. 2016 Jan;18(1):126-31. doi: 10.1093/neuonc/nov097. Epub 2015 Aug 8.

25.

Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations.

Eleveld TF, Oldridge DA, Bernard V, Koster J, Colmet Daage L, Diskin SJ, Schild L, Bentahar NB, Bellini A, Chicard M, Lapouble E, Combaret V, Legoix-Né P, Michon J, Pugh TJ, Hart LS, Rader J, Attiyeh EF, Wei JS, Zhang S, Naranjo A, Gastier-Foster JM, Hogarty MD, Asgharzadeh S, Smith MA, Guidry Auvil JM, Watkins TB, Zwijnenburg DA, Ebus ME, van Sluis P, Hakkert A, van Wezel E, van der Schoot CE, Westerhout EM, Schulte JH, Tytgat GA, Dolman ME, Janoueix-Lerosey I, Gerhard DS, Caron HN, Delattre O, Khan J, Versteeg R, Schleiermacher G, Molenaar JJ, Maris JM.

Nat Genet. 2015 Aug;47(8):864-71. doi: 10.1038/ng.3333. Epub 2015 Jun 29.

26.

Comparison of RNA-seq and microarray-based models for clinical endpoint prediction.

Zhang W, Yu Y, Hertwig F, Thierry-Mieg J, Zhang W, Thierry-Mieg D, Wang J, Furlanello C, Devanarayan V, Cheng J, Deng Y, Hero B, Hong H, Jia M, Li L, Lin SM, Nikolsky Y, Oberthuer A, Qing T, Su Z, Volland R, Wang C, Wang MD, Ai J, Albanese D, Asgharzadeh S, Avigad S, Bao W, Bessarabova M, Brilliant MH, Brors B, Chierici M, Chu TM, Zhang J, Grundy RG, He MM, Hebbring S, Kaufman HL, Lababidi S, Lancashire LJ, Li Y, Lu XX, Luo H, Ma X, Ning B, Noguera R, Peifer M, Phan JH, Roels F, Rosswog C, Shao S, Shen J, Theissen J, Tonini GP, Vandesompele J, Wu PY, Xiao W, Xu J, Xu W, Xuan J, Yang Y, Ye Z, Dong Z, Zhang KK, Yin Y, Zhao C, Zheng Y, Wolfinger RD, Shi T, Malkas LH, Berthold F, Wang J, Tong W, Shi L, Peng Z, Fischer M.

Genome Biol. 2015 Jun 25;16:133. doi: 10.1186/s13059-015-0694-1.

27.

CASC15-S Is a Tumor Suppressor lncRNA at the 6p22 Neuroblastoma Susceptibility Locus.

Russell MR, Penikis A, Oldridge DA, Alvarez-Dominguez JR, McDaniel L, Diamond M, Padovan O, Raman P, Li Y, Wei JS, Zhang S, Gnanchandran J, Seeger R, Asgharzadeh S, Khan J, Diskin SJ, Maris JM, Cole KA.

Cancer Res. 2015 Aug 1;75(15):3155-66. doi: 10.1158/0008-5472.CAN-14-3613. Epub 2015 Jun 22.

28.

Augmented expression of MYC and/or MYCN protein defines highly aggressive MYC-driven neuroblastoma: a Children's Oncology Group study.

Wang LL, Teshiba R, Ikegaki N, Tang XX, Naranjo A, London WB, Hogarty MD, Gastier-Foster JM, Look AT, Park JR, Maris JM, Cohn SL, Seeger RC, Asgharzadeh S, Shimada H.

Br J Cancer. 2015 Jun 30;113(1):57-63. doi: 10.1038/bjc.2015.188. Epub 2015 Jun 2.

29.

Exosome-mediated transfer of microRNAs within the tumor microenvironment and neuroblastoma resistance to chemotherapy.

Challagundla KB, Wise PM, Neviani P, Chava H, Murtadha M, Xu T, Kennedy R, Ivan C, Zhang X, Vannini I, Fanini F, Amadori D, Calin GA, Hadjidaniel M, Shimada H, Jong A, Seeger RC, Asgharzadeh S, Goldkorn A, Fabbri M.

J Natl Cancer Inst. 2015 May 13;107(7). pii: djv135. doi: 10.1093/jnci/djv135. Print 2015 Jul.

30.

Preservation of high glycolytic phenotype by establishing new acute lymphoblastic leukemia cell lines at physiologic oxygen concentration.

Sheard MA, Ghent MV, Cabral DJ, Lee JC, Khankaldyyan V, Ji L, Wu SQ, Kang MH, Sposto R, Asgharzadeh S, Reynolds CP.

Exp Cell Res. 2015 May 15;334(1):78-89. doi: 10.1016/j.yexcr.2015.03.024. Epub 2015 Apr 3.

PMID:
25845499
31.

Tumor-associated macrophages in SHH subgroup of medulloblastomas.

Margol AS, Robison NJ, Gnanachandran J, Hung LT, Kennedy RJ, Vali M, Dhall G, Finlay JL, Erdreich-Epstein A, Krieger MD, Drissi R, Fouladi M, Gilles FH, Judkins AR, Sposto R, Asgharzadeh S.

Clin Cancer Res. 2015 Mar 15;21(6):1457-65. doi: 10.1158/1078-0432.CCR-14-1144. Epub 2014 Oct 24.

32.

Robust selection of cancer survival signatures from high-throughput genomic data using two-fold subsampling.

Lee S, Rahnenführer J, Lang M, De Preter K, Mestdagh P, Koster J, Versteeg R, Stallings RL, Varesio L, Asgharzadeh S, Schulte JH, Fielitz K, Schwermer M, Morik K, Schramm A.

PLoS One. 2014 Oct 8;9(10):e108818. doi: 10.1371/journal.pone.0108818. eCollection 2014.

33.

Revised risk estimation and treatment stratification of low- and intermediate-risk neuroblastoma patients by integrating clinical and molecular prognostic markers.

Oberthuer A, Juraeva D, Hero B, Volland R, Sterz C, Schmidt R, Faldum A, Kahlert Y, Engesser A, Asgharzadeh S, Seeger R, Ohira M, Nakagawara A, Scaruffi P, Tonini GP, Janoueix-Lerosey I, Delattre O, Schleiermacher G, Vandesompele J, Speleman F, Noguera R, Piqueras M, Bénard J, Valent A, Avigad S, Yaniv I, Grundy RG, Ortmann M, Shao C, Schwab M, Eils R, Simon T, Theissen J, Berthold F, Westermann F, Brors B, Fischer M.

Clin Cancer Res. 2015 Apr 15;21(8):1904-15. doi: 10.1158/1078-0432.CCR-14-0817. Epub 2014 Sep 17.

34.

Pediatric brain tumor cell lines.

Xu J, Margol A, Asgharzadeh S, Erdreich-Epstein A.

J Cell Biochem. 2015 Feb;116(2):218-24. doi: 10.1002/jcb.24976.

PMID:
25211508
35.

MYCN-dependent expression of sulfatase-2 regulates neuroblastoma cell survival.

Solari V, Borriello L, Turcatel G, Shimada H, Sposto R, Fernandez GE, Asgharzadeh S, Yates EA, Turnbull JE, DeClerck YA.

Cancer Res. 2014 Nov 1;74(21):5999-6009. doi: 10.1158/0008-5472.CAN-13-2513. Epub 2014 Aug 27.

36.

PID1 (NYGGF4), a new growth-inhibitory gene in embryonal brain tumors and gliomas.

Erdreich-Epstein A, Robison N, Ren X, Zhou H, Xu J, Davidson TB, Schur M, Gilles FH, Ji L, Malvar J, Shackleford GM, Margol AS, Krieger MD, Judkins AR, Jones DT, Pfister SM, Kool M, Sposto R, Asgharzadeh S.

Clin Cancer Res. 2014 Feb 15;20(4):827-36. doi: 10.1158/1078-0432.CCR-13-2053. Epub 2013 Dec 3. Erratum in: Clin Cancer Res. 2015 Sep 15;21(18):4243. Asgharazadeh, Shahab [corrected to Asgharzadeh, Shahab].

37.

Crimean congo hemorrhagic fever appearance in the north of Iran.

Sadeghi M, Asgharzadeh SA, Bayani M, Alijanpour E, Javaniyan M, Jabbari A.

Caspian J Intern Med. 2013 Winter;4(1):617-20.

38.

Lenalidomide overcomes suppression of human natural killer cell anti-tumor functions by neuroblastoma microenvironment-associated IL-6 and TGFβ1.

Xu Y, Sun J, Sheard MA, Tran HC, Wan Z, Liu WY, Asgharzadeh S, Sposto R, Wu HW, Seeger RC.

Cancer Immunol Immunother. 2013 Oct;62(10):1637-48. doi: 10.1007/s00262-013-1466-y. Epub 2013 Aug 27.

39.

Trends in childhood brain tumor incidence, 1973-2009.

McKean-Cowdin R, Razavi P, Barrington-Trimis J, Baldwin RT, Asgharzadeh S, Cockburn M, Tihan T, Preston-Martin S.

J Neurooncol. 2013 Nov;115(2):153-60. doi: 10.1007/s11060-013-1212-5. Epub 2013 Aug 8.

40.

Medulloblastoma expresses CD1d and can be targeted for immunotherapy with NKT cells.

Liu D, Song L, Brawley VS, Robison N, Wei J, Gao X, Tian G, Margol A, Ahmed N, Asgharzadeh S, Metelitsa LS.

Clin Immunol. 2013 Oct;149(1):55-64. doi: 10.1016/j.clim.2013.06.005. Epub 2013 Jun 18.

41.

Membrane-bound TRAIL supplements natural killer cell cytotoxicity against neuroblastoma cells.

Sheard MA, Asgharzadeh S, Liu Y, Lin TY, Wu HW, Ji L, Groshen S, Lee DA, Seeger RC.

J Immunother. 2013 Jun;36(5):319-29. doi: 10.1097/CJI.0b013e31829b4493.

42.

The genetic landscape of high-risk neuroblastoma.

Pugh TJ, Morozova O, Attiyeh EF, Asgharzadeh S, Wei JS, Auclair D, Carter SL, Cibulskis K, Hanna M, Kiezun A, Kim J, Lawrence MS, Lichenstein L, McKenna A, Pedamallu CS, Ramos AH, Shefler E, Sivachenko A, Sougnez C, Stewart C, Ally A, Birol I, Chiu R, Corbett RD, Hirst M, Jackman SD, Kamoh B, Khodabakshi AH, Krzywinski M, Lo A, Moore RA, Mungall KL, Qian J, Tam A, Thiessen N, Zhao Y, Cole KA, Diamond M, Diskin SJ, Mosse YP, Wood AC, Ji L, Sposto R, Badgett T, London WB, Moyer Y, Gastier-Foster JM, Smith MA, Guidry Auvil JM, Gerhard DS, Hogarty MD, Jones SJ, Lander ES, Gabriel SB, Getz G, Seeger RC, Khan J, Marra MA, Meyerson M, Maris JM.

Nat Genet. 2013 Mar;45(3):279-84. doi: 10.1038/ng.2529. Epub 2013 Jan 20.

43.

Copy number variation signature to predict human ancestry.

Pronold M, Vali M, Pique-Regi R, Asgharzadeh S.

BMC Bioinformatics. 2012 Dec 27;13:336. doi: 10.1186/1471-2105-13-336.

44.

TARGETgene: a tool for identification of potential therapeutic targets in cancer.

Wu CC, D'Argenio D, Asgharzadeh S, Triche T.

PLoS One. 2012;7(8):e43305. doi: 10.1371/journal.pone.0043305. Epub 2012 Aug 31.

45.

Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma.

Asgharzadeh S, Salo JA, Ji L, Oberthuer A, Fischer M, Berthold F, Hadjidaniel M, Liu CW, Metelitsa LS, Pique-Regi R, Wakamatsu P, Villablanca JG, Kreissman SG, Matthay KK, Shimada H, London WB, Sposto R, Seeger RC.

J Clin Oncol. 2012 Oct 1;30(28):3525-32. Epub 2012 Aug 27.

46.

IL-15 protects NKT cells from inhibition by tumor-associated macrophages and enhances antimetastatic activity.

Liu D, Song L, Wei J, Courtney AN, Gao X, Marinova E, Guo L, Heczey A, Asgharzadeh S, Kim E, Dotti G, Metelitsa LS.

J Clin Invest. 2012 Jun;122(6):2221-33. doi: 10.1172/JCI59535. Epub 2012 May 8.

47.

Common variation at BARD1 results in the expression of an oncogenic isoform that influences neuroblastoma susceptibility and oncogenicity.

Bosse KR, Diskin SJ, Cole KA, Wood AC, Schnepp RW, Norris G, Nguyen le B, Jagannathan J, Laquaglia M, Winter C, Diamond M, Hou C, Attiyeh EF, Mosse YP, Pineros V, Dizin E, Zhang Y, Asgharzadeh S, Seeger RC, Capasso M, Pawel BR, Devoto M, Hakonarson H, Rappaport EF, Irminger-Finger I, Maris JM.

Cancer Res. 2012 Apr 15;72(8):2068-78. doi: 10.1158/0008-5472.CAN-11-3703. Epub 2012 Feb 20.

48.

Novel pathways to erythropoiesis induced by dimerization of intracellular C-Mpl in human hematopoietic progenitors.

Parekh C, Sahaghian A, Kim W, Scholes J, Ge S, Zhu Y, Asgharzadeh S, Hollis R, Kohn D, Ji L, Malvar J, Wang X, Crooks G.

Stem Cells. 2012 Apr;30(4):697-708. doi: 10.1002/stem.1046.

49.

Antibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastoma.

Carpenter EL, Haglund EA, Mace EM, Deng D, Martinez D, Wood AC, Chow AK, Weiser DA, Belcastro LT, Winter C, Bresler SC, Vigny M, Mazot P, Asgharzadeh S, Seeger RC, Zhao H, Guo R, Christensen JG, Orange JS, Pawel BR, Lemmon MA, Mossé YP.

Oncogene. 2012 Nov 15;31(46):4859-67. doi: 10.1038/onc.2011.647. Epub 2012 Jan 23. Erratum in: Oncogene. 2012 Nov 15;31(46):4888. Vigny, M [added]; Mazot, P [added].

50.

Neuroblastoma: issues in transplantation.

Grupp SA, Asgharzadeh S, Yanik GA.

Biol Blood Marrow Transplant. 2012 Jan;18(1 Suppl):S92-100. doi: 10.1016/j.bbmt.2011.10.020. Review. No abstract available.

Supplemental Content

Loading ...
Support Center